Skip to main content

Advertisement

SpringerLink
Log in

Solid Form Screenings in Pharmaceutical Development: a Perspective on Current Practices

  • Perspective
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Solid form screening is a crucial step in new drug development because solid forms of a drug substance significantly affect stability, dissolution and manufacturing processes of its drug products. This perspective introduces solid-state science from a practical standpoint, aiming to reduce knowledge gaps and promote communications among scientists with diverse background. This perspective starts with a concise overview that followed by discussion on timeline and goals of solid form screening. Techniques for solid from identification and characterization are then discussed. Subsequently, the perspective presents commonly used methods in solid form screening and introduces criteria and strategies to effectively select a favorable solid form based on screening results. The last section summarizes current practices in pharmaceutical industries and suggests potential opportunities for future research and development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

References

  1. Brittain HG. Polymorphism in Pharmaceutical Solids. 2nd Ed. Informa Healthcare; 2009.

    Google Scholar 

  2. Bauer J, Spanton S, Henry R, Quick J, Dziki W, Porter W, Morris J. Ritonavir: An Extraordinary Example of Conformational Polymorphism. Pharm Res. 2001;18:859–66.

    Article  CAS  PubMed  Google Scholar 

  3. Karpinski PH. Polymorphism of Active Pharmaceutical Ingredients. Chem Eng Tech. 2006;29:233–7.

    Article  CAS  Google Scholar 

  4. Byrn SR. Solid-State Chemistry of Drugs. SSCI; 1999.

    Google Scholar 

  5. Davey RJ, Garside J. From Molecules to Crystallizers: An Introduction to Crystallization. Oxford University Press; 2001.

    Google Scholar 

  6. Hilfiker R. Polymorphism in the Pharmaceutical Industry. Wiley-VCH; 2006.

    Book  Google Scholar 

  7. Bernstein J. Polymorphism in Molecular Crystals. International Union of Crystallography; 2008.

    Google Scholar 

  8. Byrn SR, Zografi G, Chen X. Solid-State Properties of Pharmaceutical Materials. Wiley; 2017.

    Book  Google Scholar 

  9. Storey RA, Ymén I. Solid State Characterization Pf Pharmaceuticals. John Wiley & Sons; 2011.

    Book  Google Scholar 

  10. Vippagunta SR, Brittain HG, Grant DJW. Crystalline Solids. Adv Drug Deliv Rev 2001;48:3–26.

  11. Yu L. Amorphus pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Review. 2001;48:27–42.

    Article  CAS  Google Scholar 

  12. Rams-Baron M, Jachowicz R, Boldyreva E, Zhou D, Jamroz W, Paluch M. Amorphous Drugs: Benefits and Challenges. 1st Ed. Springer; 2018.

    Book  Google Scholar 

  13. Gui Y, McCann EC, Yao X, Li Y, Jones KJ, Yu L. Amorphous Drug-Polymer Salt with High Stability under Tropical Conditions and Fast Dissolution: The Case of Clofazimine and Poly(Acrylic Acid). Mol Pharmceutics. 2021;18:1364–1372.

    Article  CAS  Google Scholar 

  14. Teerakapibal R, Gui Y, Yu L. Gelatin Nano-Coating for Inhibiting Surface Crystallization of Amorphous Drugs. Pharm Res. 2018;35:23.

  15. Frank DS, Matzger AJ. Effect of polymer hydrophobicity on the stability of amorphous solid dispersions and supersaturated solutions of a hydrophobic pharmaceutical. Mol Pharmacuetics. 2019;16:682–8.

    Article  CAS  Google Scholar 

  16. Jones CG, Martynowycz MW, Hattne J, Fulton TJ, Stoltz BM, Rodriguez JA, Nelson HM, Gonen T. The CryoEM Method microED as a Powerful Tool for Small Molecule Structure Determination. ACS Cent Sci. 2018;4:1587–1592.

  17. Nishiyama Y, Hou G, Agarwal V, Su Y, Ramamoorthy A. Ultrafast magic angle spinning solid-state NMR spectroscopy: advances in methodology and applications. Chem Rev. 2023;123:918–88.

    Article  CAS  PubMed  Google Scholar 

  18. Du Y, Phyo P, Li M, Sorman B, McNevin M, Xu W, Liu Y, Su Y. Quantifying Micromolar Crystallinity in Pharmaceutical Materials Utilizing 19F Solid-State NMR. Anal Chem. 2022;94:15341–15349.

  19. Lu X, Li M, Huang C, Lowinger MB, Xu W, Yu L, Byrn SR, Templeton AC, Su Y. Atomic-Level Drug Substance and Polymer Interaction in Posaconazole Amorphous Solid Dispersion from Solid-State NMR. Mol Pharmaceutics 2020;17:2585–2598.

  20. Holmes ST, Engl OG, Srnec MN, Madura JD, Quiñones R, Harper JL, Schurko RW, Iuliucci RJ. Chemical Shift Tensors of Cimetidine Form a Modeled with Density Functional Theory Calculations: Implications for NMR Crystallography. J Phys Chem A. 2020;124:3109–3119.

  21. Sun C. Chapter 7: Mechanical Properties. In: Li T, Mattei a. Pharmaceutical Crystals: Science and Engineering. John Wiley & Sons, Inc.; 2018. 273–296.

  22. Paul S, Sun CC. Gaining Insight into Tablet Capping Tendency from Compaction Simulation. Int J Pharm. 2017;524:111–120.

  23. Gui Y, Yao X, Guzei I, Aristov MM, Yu J, Yu L. A Mechanism for reversible solid-state transitions involving nitro torsion. Chem Mater. 2020;32:7754–65.

    Article  CAS  Google Scholar 

  24. Yao X, Henry RF, Zhang GGZ. Ritonativr Form III: A New Polymorph after 24 Years. J Pharm Sci. 2023;112:237–242.

  25. Chen S, Guzei IA, Yu L. New polymorphs of ROY and new record for coexisting polymorphs of solved structures. J Am Chem Soc. 2005;127:9881–5.

    Article  CAS  PubMed  Google Scholar 

  26. Shtukenberg AG, Tan M, Vogt-Maranto L, Chan EJ, Xu W, Yang J, Tuckerman ME, Hu CT, Kahr B. Melt Crystallization for paracetamol polymorphism. Cryst Growth Des. 2019;19:4070–80.

    Article  CAS  Google Scholar 

  27. Guerain M. A review on high pressure experiments for study of crystallographic behavior and polymorphism of pharmaceutical materials. J Pharm Sci. 2020;109:2640–53.

    Article  CAS  PubMed  Google Scholar 

  28. Miglani Bhardwaj R, Ho R, Gui Y, Brackemeyer P, Schneider-Rauber G, Nordstrom FL, Sheikh AY. Origins and Implications of Extraordinarily Soft Crystals in a Fixed-Dose Combination Hepatitis C Regimen. Cryst Growth Des. 2022;22:4250–9.

    Article  CAS  Google Scholar 

  29. Chen S, Xi H, Yu L. Cross-nucleation between roy polymorphs. J Am Chem Soc. 2005;127:17439–44.

    Article  CAS  PubMed  Google Scholar 

  30. Mitchell CA, Yu L, Ward MD. Selective nucleation and discovery of organic polymorphs through epitaxy with single crystal substrates. J Am Chem Soc. 2001;123:10830–9.

    Article  CAS  PubMed  Google Scholar 

  31. Yao X, Liu Q, Wang B, Yu J, Aristov MM, Shi C, Zhang GGZ, Yu L. Anisotropic molecular organization at a liquid/vapor interface promotes crystal nucleation with polymorph selection. J Am Chem Soc. 2022;144:11638–45.

    Article  CAS  PubMed  Google Scholar 

  32. Stahl PH, Wermuth CG. Pharmaceutical salts: properties, selection and use. Wiley; 2002.

    Google Scholar 

  33. Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: a review of preparations, physicochemical properties and applications. Acta Pharm Sin B. 2021;11:2537–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Gui Y, Jin Y, Ruan S, Sun G, López-Mejías V, Yu L. Crystal energy landscape of nifedipine by experiment and computer prediction. Cryst Growth Des. 2022;22:1365–70.

    Article  CAS  Google Scholar 

  35. Neumann MA, Van de Streek J. How many ritonavir cases are there still out there? Faraday Discuss. 2018;211:441–58.

    Article  CAS  PubMed  Google Scholar 

  36. Sheikh AY, Mattei A, Miglani Bhardwaj R, Hong RS, Abraham NS, Schneider-Rauber G, Engstrom KM, Diwan M, Henry RF, Gao Y, Juarez V, Jordan E, DeGoey DA, Hutchins CW. Implications of the conformationally flexible, macrocyclic structure of the first-generation, direct-acting anti-viral paritaprevir on its solid form complexity and chameleonic behavior. J Am Chem Soc. 2021;143:17479–91.

    Article  CAS  PubMed  Google Scholar 

  37. Hong RS, Miglani Bhardwaj R, Henry R, Mattei A, Diwan M, Thomas A, Danzer GD, Sheikh AY. Distinct hybrid hydrates of paritaprevir: combined experimental and computational assessment of their hydration−dehydration behavior and implications for regulatory controls. Cryst Growth Des. 2022;22:726–37.

    Article  CAS  Google Scholar 

  38. Newmann A, Knipp G, Zografi G. Assessing the Performance of Amorphous Solid Dispersions. J Pharm Sci. 2012;101:1355–1377.

  39. Acharya KR, Kuchela KN. Crystal Structure of Sulfamerazine. J Crystal Spect Res. 1982;12:369–376.

  40. Zhang GGZ, Gu C, Zell MT, Burkhardt RT, Munson EJ, Grant DJW. Crystallization and Transitions of Sulfamerazine Polymorphs. J Pharm Sci. 2002;91:1089–1100.

  41. Sun C, Grant DJW. Influence of Crystal Structure on the Tableting Properties of Sulfamerazine Polymorphs. Pharm Res. 2001;18:274–280.

  42. Reutzel-Edens SM. Computer-aided solid form design. CrystEngComm. 2022;24:431–3.

    Article  CAS  Google Scholar 

  43. Mattei A, Hong RS, Dietrich H, Firaha D, Helfferich J, Liu YM, Sasikumar K, Abraham NS, Miglani Bhardwaj R, Neumann MA, Sheikh AY. J Chem Theory Comput. 2022;18:5725–5738.

Download references

Author information

Authors and Affiliations

  1. China Innovation Center of Roche, Building 5, 371 Lishizhen Road, Shanghai, China

    Yue Gui

Authors
  1. Yue Gui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yue Gui.

Ethics declarations

Conflict of Interest

The author declare no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gui, Y. Solid Form Screenings in Pharmaceutical Development: a Perspective on Current Practices. Pharm Res 40, 2347–2354 (2023). https://doi.org/10.1007/s11095-023-03573-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-023-03573-2

Keywords

Search

Navigation